TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01556776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: placebo or lenalidomide 5 mg daily on days 1-28 of the first 28-day cycle. If the 5 mg dose level is well tolerated, escalation to 10 mg daily on days 1-28 of cycle 2-6 is permitted; further escalations starting with the 7th cycle and up to the 12th cycle to 15 mg daily is permitted. If after 12 cycles of treatment subjects still present with MRD levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 13th cycle up to progression 20 mg daily is permitted. If after 18 cycles of treatment for subjects still present with MRD.levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 19th cycle up to progression 25 mg daily is permitted. 25 mg is the maximal daily dose of lenalidomide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo or lenalidomide 5 mg daily on days 1-28 of the first 28-day cycle. If the 5 mg dose level is well tolerated, escalation to 10 mg daily on days 1-28 of cycle 2-6 is permitted; further escalations starting with the 7th cycle and up to the 12th cycle to 15 mg daily is permitted. If after 12 cycles of treatment subjects still present with MRD levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 13th cycle up to progression 20 mg daily is permitted. If after 18 cycles of treatment for subjects still present with MRD.levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 19th cycle up to progression 25 mg daily is permitted. 25 mg is the maximal daily dose of lenalidomide
Study: NCT05454059

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saliva Sample Collection
Description: Saliva samples were collected from all subjects in the morning. Unstimulated saliva from each patient was collected by standard defined spitting method without stimulation.
Study: NCT00679263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MN-221
Description: Initial dose: 16 μg/min for 15 minutes followed by 8 μg/min for 105 minutes (2-hour infusion with a total dose of 1,080 μg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MN-221
Description: Subsequent dose: 30 μg/min for 15 minutes followed by 15 μg/min for 45 minutes (1-hr infusion with a total dose of 1,125 μg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravenous infusion with dosing volume equivalent to active treatment.
Study: NCT03202797

Intervention type: OTHER
Intervention: audiometric tests
Description: tone and speech audiometry

Intervention type: OTHER
Intervention: Questionnaires
Description: APHAB (Abbreviate Profile of Hearing Aid Benefit), HISQUI (Hearing Implant Sound Quality Index), Munich music questionnaire

Intervention type: OTHER
Intervention: Settings of cochlear implants
Description: pitch matching, evolutionary algorithm setting
Study: NCT04034420

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online training platform
Description: Self-paced training and learning materials in relation to family services
Study: NCT05454059

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saliva Sample Collection
Description: Saliva samples were collected from all subjects in the morning. Unstimulated saliva from each patient was collected by standard defined spitting method without stimulation.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: HbA1c Level
Description: Measurement of HbA1c levels from blood tests
Study: NCT03484832

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Walter Ritter Ethyl Chloride Spray
Description: Participants receive an application of EMLA or placebo cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed from a distance of 30 cm for 5 seconds or until the skin was blanched, then intra-articular injection of shoulder is performed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Spray
Description: Participants receive an application of EMLA or placebo cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed using placebo spray (Evain Eau Minerale Naturelle, a pure water spray with hydrocarbon propellant), then intra-articular injection of shoulder is performed.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Spray
Description: Participants receive an application of EMLA or placebo cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed using placebo spray (Evain Eau Minerale Naturelle, a pure water spray with hydrocarbon propellant), then intra-articular injection of shoulder is performed.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Description: Participants receive an application of placebo cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed using Walter Ritter Ethyl chloride spray or placebo spray, then intra-articular injection of shoulder is performed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Cream
Description: Participants receive an application of placebo cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed using Walter Ritter Ethyl chloride spray or placebo spray, then intra-articular injection of shoulder is performed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA Cream
Description: Participants receive an application of EMLA cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed using Walter Ritter Ethyl chloride spray or placebo spray, then intra-articular injection of shoulder is performed.
Study: NCT03351556

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Arm 1
Description: Participants in this arm will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 10,000 TZS/month conditional on visit attendance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Arm 2
Description: Participants in this arm will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 22,500 TZS/month conditional on visit attendance.
Study: NCT05454059

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HbA1c Level
Description: Measurement of HbA1c levels from blood tests
Study: NCT02687217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxygen
Description: Hyperoxygenation ≥50% of oxygen by mask(non-rebreathing) was given through out the surgery.~Received 6L/min of oxygen through venturimask upto 2 hours in post operative period.~Hyperoxygenation refers to provision of ≥50% of oxygen by mask(non-rebreathing) through out the surgery.
Study: NCT03761940

Intervention type: OTHER
Intervention: EQ5D questionnaire and a demographic questionnaire
Description: questionnaires
Study: NCT05454059

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: HbA1c Level
Description: Measurement of HbA1c levels from blood tests

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HbA1c Level
Description: Measurement of HbA1c levels from blood tests
Study: NCT00822900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Following a one hour loading dose of 0.714 mg/kg per infusion pump through a dedicated IV line, the study drug (progesterone or placebo) will be administered as a continuous intravenous infusion at 0.5 mg/kg/hr for 71 hours, then tapered over an additional 24 hours. To simplify the infusion protocol, a weight based dosing table will be used by the on-sight pharmacy to mix the correct dose for a 10 cc/hour continuous infusion over the 71 hour steady state period followed by three additional 8-hour decrements (7.5 cc/hr-5.0 cc/hr-2.5 cc/hr) to zero, for a total treatment duration of 96 hour. The progesterone/placebo will be combined with a 20% Intralipid mixture for infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo stock solution is the ethanol diluent required for dissolving progesterone. The volume of placebo to be mixed with intralipid is based on the mg/kg/hr volume. Using an infusion pump through a dedicated IV line - a one hour loading dose of placebo plus intralipid is administered as a continuous intravenous infusion for 71 hours, then tapered over an additional 24 hours.
Study: NCT01939249

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Abbott Laboratories Xience

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biotronik Orsiro
Study: NCT00895245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fosaprepitant dimeglumine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palonosetron hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV and orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Living Index-Emesis Questionnaire
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emesis Diary
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Undergo radiotherapy
Study: NCT00509743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous diclofenac sodium (DIC075V)
Description: High dose Diclofenac

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous diclofenac sodium (DIC075V)
Description: Low Dose Diclofenac
Study: NCT01628367

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally Traumatic Tooth Extraction
Description: The surgeon will perform a minimally traumatic tooth extraction in the following fashion. Intrasulcular incisions will be performed with at 15-C scalpel around the tooth to be extracted.~A periotome will then be introduced into the periodontal ligament space in order to sever the subcrestal attachment and expand the periodontal ligament space. Elevators will be used to initiate luxation of teeth. After significant mobility has been achieved through elevation, forceps will be used only to deliver the tooth. Finally, the socket will be curetted to remove all granulomatous tissue and irrigated with sterile isotonic saline solution.
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain jelly control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain jelly control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain jelly control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain jelly control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain jelly control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain jelly control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain jelly control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain jelly control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain jelly control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain jelly control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain jelly control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain jelly control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain jelly control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain jelly control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain jelly control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain jelly control

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Plain jelly control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain jelly control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain jelly control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain jelly control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain jelly control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain jelly control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain jelly control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Paracetamol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Paracetamol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Paracetamol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Paracetamol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Paracetamol
Study: NCT01628367

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally Traumatic Tooth Extraction
Description: The surgeon will perform a minimally traumatic tooth extraction in the following fashion. Intrasulcular incisions will be performed with at 15-C scalpel around the tooth to be extracted.~A periotome will then be introduced into the periodontal ligament space in order to sever the subcrestal attachment and expand the periodontal ligament space. Elevators will be used to initiate luxation of teeth. After significant mobility has been achieved through elevation, forceps will be used only to deliver the tooth. Finally, the socket will be curetted to remove all granulomatous tissue and irrigated with sterile isotonic saline solution.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Implant Placement
Description: A threaded titanium alloy implant with an internal hex connection and a Resorbable Blast Texturing (RBT) surface (Tapered Internal® Implant System, Biohorizons, Inc., Birmingham, AL, USA) will be placed using a surgical guide. Implant diameter of 3.8mm with lengths of either 12 or 15mm will be used. Implants will be placed approximately 3-4mm below the free gingival margin or 2-3mm below the cemento-enamel junction of adjacent teeth.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immediate Implant Placement
Description: A threaded titanium alloy implant with an internal hex connection and a Resorbable Blast Texturing (RBT) surface (Tapered Internal® Implant System, Biohorizons, Inc., Birmingham, AL, USA) will be placed using a surgical guide. Implant diameter of 3.8mm with lengths of either 12 or 15mm will be used. Implants will be placed approximately 3-4mm below the free gingival margin or 2-3mm below the cemento-enamel junction of adjacent teeth.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bone Graft Placement
Description: Circumferential defects or dehiscences around the immediately placed implant will be grafted. enCore™ Combination Allograft (Osteogenics Biomedical, Lubbock, Texas, USA) will be used as the bone graft material.
Study: NCT00831506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: digoxin
Description: digoxin once daily (0.125 mg QD) plus placebo three times daily (TID), 8 hours apart for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: digoxin
Description: digoxin once daily (0.125 mg QD) for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimebon
Description: Dimebon three times a day, 8 hours apart for 14 days (10 mg TID on Days 1-7 and 20 mg TID on Days 8-14).
Study: NCT01802424

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Friends program
Description: The Friends program is a ten weeks group interventions based on principles from Cognitive Behavioural Therapy aimed at ameliorating symptoms of anxiety and depression in children and adolescents. There are age-specific versions of the manual, one for children 8-12 years and one for adolescents 12-15 years.
Study: NCT00690404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2066
Description: single oral dose
Study: NCT02408913

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-EBOMVA079-00-VP (MVA-EbolaZ)
Description: Ebola Modified Vaccinia Virus Ankara Vaccine
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Paracetamol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Paracetamol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Paracetamol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Paracetamol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Paracetamol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Paracetamol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Paracetamol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Paracetamol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Paracetamol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Paracetamol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Apple compote Paracetamol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Apple compote Paracetamol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Paracetamol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Paracetamol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Paracetamol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Paracetamol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Paracetamol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Paracetamol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Furosemide
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Furosemide

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Furosemide

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Furosemide
Study: NCT02408913

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-EBOMVA079-00-VP (MVA-EbolaZ)
Description: Ebola Modified Vaccinia Virus Ankara Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-EBOMVA079-00-VP (MVA-EbolaZ)
Description: Ebola Modified Vaccinia Virus Ankara Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-EBOADC069-00-VP (cAd3-EBO)
Description: Ebola Chimpanzee Adenovirus Vector Vaccine
Study: NCT04255225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking for 10 minutes
Description: Participants will walk on a treadmill for 10 minutes at a moderate intensity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking for 20 minutes
Description: Participants will walk on a treadmill for 20 minutes at a moderate intensity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking for 30 minutes
Description: Participants will walk on a treadmill for 30 minutes at a moderate intensity.
Study: NCT01553266

Intervention type: BEHAVIORAL
Intervention: Mobile Diabetes Education Teams intervention
Description: A MDET (one Registered Nurse and Registered Dietician) supports primary care physicians by providing diabetes management education to the PCPs' patients onsite, one to four times a month based on patient volume.
Study: NCT02535221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin+TAM+AI
Description: Goserelin 3.6mg subcutaneous injection per 4 weeks, for 16-20weeks. TAM 10mg oral twice a day for the first four weeks(to wait the Goserelin start to work in body) than change to AI 1mg oral once a day with Goserelin for the next 12-16 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin+CTX+5-Fu
Description: Epirubicin(80-100 mg/m2 Q21 days) + CTX(600 mg/m2 Q 21days) + 5-Fu (600 mg/m2 Q21 days or 200 mg/m2 •day from Day1 to day 21) for four to six cycles.
Study: NCT01702259

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia Scanner device (GLS)
Description: The Erchonia® GLS device is made up of six independent diodes, each emitting 17 milliwatts (mW), 532 nanometer (nm) of green laser light.
Study: NCT03761940

Intervention type: OTHER
Intervention: EQ5D questionnaire and a demographic questionnaire
Description: questionnaires

Intervention type: OTHER
Intervention: EQ5D questionnaire and a demographic questionnaire
Description: questionnaires
Study: NCT01702259

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo device
Description: Inactive Erchonia GLS.
Study: NCT00792337

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: 10 mg per oral once daily for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: B1-6-12
Description: 1 table per day for 8 weeks
Study: NCT01787032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113608
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113608
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113608
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: tablet